手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| 費用対効果分析 (CEA)× | Quality-Adjusted Life Year (QALY)× | |
|---|---|---|
| 分野 | 医療経済学 | 医療経済学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1984 | 1985 |
| 提唱者≠ | Drummond & Stoddart (Health Economics Research Group, McMaster University) | Alan Williams (Health Economics Research Centre, Oxford University) |
| 種類 | Method | Method |
| 原典≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| 別名≠ | CEA, ICER, Incremental Cost-Effectiveness Ratio | QALY, health utility measure |
| 関連 | 5 | 5 |
| 概要≠ | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGateデータセット ↗ |
|
|